BioNTech SE (BNTX) FCF Payout Ratio: 34.13%
The FCF payout ratio for BioNTech SE (BNTX) is 34.13%. It is above its 12-month average by 831.24% (3.67%).
BNTX FCF Payout Ratio Chart
BNTX Average FCF Payout Ratio Chart
BNTX Current vs Average FCF Payout Ratio Chart
BNTX FCF Payout Ratio Metrics
FCF PAYOUT RATIO
34.13%
FCF PAYOUT RATIO AVG TTM
3.67%
FCF PAYOUT RATIO AVG 3Y
3.67%
FCF PAYOUT RATIO AVG 5Y
3.67%
FCF PAYOUT RATIO AVG 10Y
3.67%
FCF PAYOUT RATIO AVG 15Y
3.67%
FCF PAYOUT RATIO AVG 20Y
3.67%
CURRENT VS TTM AVG
+831.24%
CURRENT VS 3Y AVG
+831.24%
CURRENT VS 5Y AVG
+831.24%
CURRENT VS 10Y AVG
+831.24%
CURRENT VS 15Y AVG
+831.24%
CURRENT VS 20Y AVG
+831.24%
Payout Ratio Comparison
FCF Payout Ratio
34.1%
Earnings Payout Ratio
N/A
Dividend Yield
2.45%
FCF Yield
6.86%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $316.92M | $0 | 0.0% |
| 2024 | ($253.28M) | $0 | N/A (Loss) |
| 2023 | $5.15B | $0 | 0.0% |
| 2022 | $14.14B | $518.17M | 3.7% |
| 2021 | $837.48M | $0 | 0.0% |
| 2020 | ($120.81M) | $0 | N/A (Loss) |
| 2019 | ($302.55M) | $0 | N/A (Loss) |
| 2018 | ($144.24M) | $0 | N/A (Loss) |
| 2017 | ($132.42M) | $0 | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
BioNTech SE FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE FCF Payout Ratio FAQ
- What is the FCF payout ratio for BioNTech SE (BNTX)?
- The FCF payout ratio for BNTX stock is 34.13%.
- What is the TTM average FCF payout ratio for BioNTech SE (BNTX)?
- The TTM average FCF payout ratio for BNTX stock is 3.67%.
- What is the 3Y average FCF payout ratio for BioNTech SE (BNTX)?
- The 3Y average FCF payout ratio for BNTX stock is 3.67%.
- What is the 5Y average FCF payout ratio for BioNTech SE (BNTX)?
- The 5Y average FCF payout ratio for BNTX stock is 3.67%.
- What is the 10Y average FCF payout ratio for BioNTech SE (BNTX)?
- The 10Y average FCF payout ratio for BNTX stock is 3.67%.
- What is the 15Y average FCF payout ratio for BioNTech SE (BNTX)?
- The 15Y average FCF payout ratio for BNTX stock is 3.67%.
- What is the 20Y average FCF payout ratio for BioNTech SE (BNTX)?
- The 20Y average FCF payout ratio for BNTX stock is 3.67%.
BioNTech SE FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2022-12-31 | 3.67% |
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin